STAT3 and cancer: Remarkably, after two treatment cycles, one patient achieved PR, and no serious TRAEs were reported, emphasizing the safety profile of KT-333.505 These advancements in STAT3-targeting PROTACs exemplify significant strides in the development of new cancer therapies, particularly in effectively targeting transcription factors which are previously deemed as challenge due to the lack of conventional binding sites.